Vertex Reaches Agreement With NHS England for Cystic Fibrosis Medicines

Vertex has worked out a pricing deal with NHS England to supply its currently licensed cystic fibrosis medicines for patients covered by the national health service.  

Under the agreement, patients aged two and older with cystic fibrosis can be prescribed Orkambi (lumacaftor/ivacaftor) and patients ages 12 years and older with a more severe form of CF can be prescribed Symkevi (tezacaftor/ivacaftor) in combination with Kalydeco (ivacaftor).

The agreement also offers expanded access to Kalydeco for individuals aged 18 and older who have the R117H mutation and to patients ages 12 months and older who have one of nine gating mutations.